Hypotension - Pipeline Review, H1 2017

  • ID: 4091137
  • Report
  • 43 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Anexon Inc
  • BCO Pharma Ltd
  • Theravance Biopharma Inc
  • TrioxBio Inc
  • MORE
Hypotension - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Hypotension - Pipeline Review, H1 2017, provides an overview of the Hypotension (Cardiovascular) pipeline landscape.

Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Treatment is required for patients with signs and symptoms.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Hypotension - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypotension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypotension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypotension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 3 and 1 respectively.

Hypotension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypotension (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Hypotension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypotension (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypotension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypotension (Cardiovascular).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypotension (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypotension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Anexon Inc
  • BCO Pharma Ltd
  • Theravance Biopharma Inc
  • TrioxBio Inc
  • MORE
Introduction

Hypotension - Overview

Hypotension - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hypotension - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypotension - Companies Involved in Therapeutics Development

Anexon Inc

BCO Pharma Ltd

La Jolla Pharmaceutical Company

Theravance Biopharma Inc

TrioxBio Inc

Hypotension - Drug Profiles

angiotensin II acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANX-042 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dopamine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTR-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTR-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-9855 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypotension - Dormant Projects

Hypotension - Product Development Milestones

Featured News & Press Releases

Feb 27, 2017: La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501

Nov 30, 2015: La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501

Feb 09, 2015: La Jolla Pharmaceutical Company Announces Special Protocol Assessment for Planned Phase 3 Trial of LJPC-501 in Catecholamine-Resistant Hypotension

Jul 08, 2014: La Jolla Pharmaceutical Company Announces Planned Initiation of Phase 3 Registration Program for LJPC-501 in Resistant Hypotension

Nov 19, 2008: Chelsea Therapeutics Completes Enrollment In Phase II Trial Of Droxidopa In Intradialytic Hypotension

Nov 19, 2008: Chelsea Therapeutics Completes Enrollment In Phase II Trial Of Droxidopa In Intradialytic Hypotension

Nov 03, 2008: Chelsea Therapeutics Reports Significant Reduction In Severity Of Symptoms During Titration Phase Of Pivotal Droxidopa Study In Neurogenic Orthostatic Hypotension

Oct 29, 2008: Data From Chelsea Therapeutics Phase III Trial Of Droxidopa in Neurogenic Orthostatic Hypotension To Be Presented At 19th Annual International Symposium On The Autonomic Nervous System

Sep 02, 2008: Chelsea Therapeutics Begins Patient Dosing In Second Pivotal Phase III Trial Of Droxidopa In Neurogenic Orthostatic Hypotension

Aug 26, 2008: Chelsea Therapeutics Receives Fast Track Designation For Droxidopa For Symptomatic Neurogenic Orthostatic Hypotension

Feb 07, 2008: Chelsea Therapeutics Begins Patient Dosing In Pivotal Phase III Trial Of Droxidopa In Neurogenic Orthostatic Hypotension

Nov 12, 2007: FDA Accepts Chelsea Therapeutics Investigational New Drug Application For Droxidopa

Aug 14, 2007: European Commission Grants Chelsea Therapeutics Two Orphan Medicinal Product Designations For Droxidopa

Jan 22, 2007: FDA Grants Chelsea Therapeutics Orphan Drug Designation For Droxidopa

Jan 11, 2007: Chelsea Therapeutics Announces Results Of European Phase IIb Trial Of Droxidopa

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Hypotension, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Hypotension - Pipeline by Anexon Inc, H1

Hypotension - Pipeline by BCO Pharma Ltd, H1

Hypotension - Pipeline by La Jolla Pharmaceutical Company, H1

Hypotension - Pipeline by Theravance Biopharma Inc, H1

Hypotension - Pipeline by TrioxBio Inc, H1

Hypotension - Dormant Projects, H1

List of Figures:

Number of Products under Development for Hypotension, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Anexon Inc
  • BCO Pharma Ltd
  • La Jolla Pharmaceutical Company
  • Theravance Biopharma Inc
  • TrioxBio Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll